The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. NEW YORK and LONDON, Jan. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

NOVEMBER 16, 2020

“It is truly a pleasure to sponsor and fund this critical trial developed by Dr. Alexander,” says Marcille Pilkington, Co-founder, President, and CEO of Tulip Medical. Alexander’s work thus far treating COPD and FLD patients who have run out of options is inspiring.

Trials 52

Trials Clinical Trials Clinical Trials Dermatology 52

The Pharma Data

NOVEMBER 12, 2020

Finasteride was developed to shrink enlarged prostates, a condition called benign prostatic hyperplasia. Trinh’s team used data from VigiBase, which gathers information from 153 countries on all adverse drug reactions and contains more than 20 million safety reports. 11 in JAMA Dermatology. © 2020 HealthDay.

Dermatology 52

Dermatology Drugs Packaging Packaging 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — Mothers who drink cow’s milk while breastfeeding may reduce their child’s risk of developing food allergies , a new Swedish study suggests. It could be that milk in the mother’s diet contains substances that stimulate the child’s immune system to mature. MONDAY, Jan.

Allergies 52

Allergies Doctor Doctors Dermatology 52

The Pharma Data

OCTOBER 15, 2020

is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. IRVINE, Calif., per share, for gross proceeds of $88.0 Tarsus Pharmaceuticals, Inc.

Containment 40

Containment Dermatology Sales Marketing 40

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

NOVEMBER 4, 2020

Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

The Pharma Data

DECEMBER 15, 2020

NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Approval demonstrates our ability to execute upon the entirety of the drug development and registration process.

FDA Approval 52

FDA Approval Development Production Drugs 52

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. The performance remained ahead of competition with growth momentum in the Dermatology and Nutritionals categories, with business up by 6.6

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JULY 11, 2021

Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. The efficacy of TAKHZYRO to prevent HAE attacks over the long term will be an important consideration for patients and physicians as they develop a treatment plan for patients that is focused on reducing the number of HAE attacks.”. “For

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

FEBRUARY 22, 2022

AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% New inhalers would have near-zero Global Warming Potential propellant. AstraZeneca also announces all imported electricity coming from renewable sources and sets new supplier targets.

Development 52

Development Medicine Containment Dermatology 52

The Pharma Data

AUGUST 19, 2020

Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 Global Head of Janssen Research & Development, Johnson & Johnson. “We NEW BRUNSWICK, N.J., Nipocalimab recently received a rare pediatric disease designation from the U.S.

Production 52

Production Dermatology Development Containment 52

The Pharma Data

AUGUST 19, 2020

Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 Global Head of Janssen Research & Development , Johnson & Johnson. NEW BRUNSWICK, N.J. , Nipocalimab recently received a rare pediatric disease designation from the U.S. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

OCTOBER 26, 2020

“Atopic dermatitis is a serious, unpredictable, and often debilitating condition that can have a significant impact on the daily lives of patients and their families,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We About Abrocitinib.

Clinical Trials 40

Clinical Trials Clinical Trials Medicine Trials 40

The Pharma Data

MARCH 3, 2021

Symbicort (budesonide/formoterol) is a combination formulation containing budesonide, an inhaled corticosteroid that treats underlying inflammation, and formoterol, a long-acting beta2-agonist bronchodilator with a fast onset of action, in a single inhaler. AstraZeneca.

Dermatology 52

Dermatology Drug Delivery Medicine Containment 52

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14. IR main line: Tel.: +33

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

Druggist

MARCH 17, 2021

Antibacterial drugs such as lymecycline kill bacteria and stop acne development. . Freederm gel contains Vitamin B complex (Nicotinamide) which reduces spot size, redness and inflammation. Strauss JS, Krowchuk DP, Leyden JJ, American Academy of Dermatology/American Academy of Dermatology Association, et al.

Bacteria 59

Bacteria Dermatology Doctor Doctors 59

Bioengineer

JULY 20, 2021

We look forward to partnering with patient organizations and the medical community to develop educational and other support programs that will serve dermatomyositis patients.” Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

The Pharma Data

DECEMBER 30, 2020

billion acquisition of Germany-based Myr GmbH, a company focused on developing therapies for treatment of chronic hepatitis delta virus (HDV), the most severe form of viral hepatitis. AstraZeneca Dives into Rare Diseases: AstraZeneca has been in the spotlight for the COVID-19 vaccine candidate it developed with Oxford University.

Antibody 52

Antibody Allergies Branding Dermatology 52

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. 1] as determined by an FDA-approved test.

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

AUGUST 17, 2021

Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. GSK is responsible for the ongoing research, development, commercialization, and manufacture of each of these Products under the Agreement. Immune-Mediated Dermatologic Adverse Reactions.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

Delveinsight

AUGUST 13, 2020

GSK is developing this therapy in collaboration with Innoviva, Inc., It contains fluticasone furoate, an inhaled corticosteroid, umeclidinium, a long-acting muscarinic antagonist; and vilanterol, a long-acting beta2-adrenergic agonist, delivered in GSK’s Ellipta dry powder inhaler.

Antibody 40

Antibody Medicine Trials Development 40

The Pharma Data

MARCH 11, 2021

development lead, gastrointestinal cancers, Bristol Myers Squibb. “In Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. Waxman, M.D.,

Trials 52

Trials Hormones Genomics Genome 52

The Pharma Data

JULY 23, 2021

For the past three and a half years, Opdivo monotherapy has been an important option that physicians have relied on to address this need and is currently the most commonly used therapy in the post-sorafenib setting,” said Jonathan Cheng, senior vice president and head of oncology development, Bristol Myers Squibb.

Hormones 52

Hormones Trials Genomics Genome 52

The Pharma Data

AUGUST 11, 2020

development lead, Gastrointestinal Cancers, Bristol Myers Squibb. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients. To date, the Opdivo clinical development program has treated more than 35,000 patients. Waxman, M.D.,

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

development lead, Gastrointestinal Cancers, Bristol Myers Squibb. “We We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients. To date, the Opdivo clinical development program has treated more than 35,000 patients. Waxman, M.D.,

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

Pfizer

JANUARY 27, 2023

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. difficile may need to be discontinued.

Bacteria 75

Bacteria Medicine Containment Manufacturing 75

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

(NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccine Vaccination Trials 52

The Pharma Data

APRIL 4, 2023

Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. Additionally, there has been increasing complexity in clinical trial designs and an overall higher cost of drug development.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

The Pharma Data

JANUARY 26, 2021

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The company assumes no obligation to update any information contained herein.”. Dr. Reddy’s operates in markets across the globe. For more information, log on to: www.drreddys.com.

Life Science 40

Life Science Production Marketing Dermatology 40

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. Novartis is collaborating with Molecular Partners to develop, manufacture and commercialize two antiviral DARPin ® candidates, ensovibep (MP0420) and MP0423. Diovan Group. Exjade/Jadenu.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

JANUARY 24, 2021

Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. VP-102 is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidim delivered by way of a single-use applicator. Read on to see. COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

Pfizer

OCTOBER 28, 2022

1,2,3 As the developer of tofacitinib, Pfizer is committed to advancing the science of Janus kinase inhibition and enhancing understanding of tofacitinib through robust clinical development programs in the treatment of immune-mediated inflammatory conditions. SERIOUS INFECTIONS.

Clinical Trials 40

Clinical Trials Clinical Trials Vaccine Vaccination 40